Skip to main content

Table 2 Treatment-related adverse events that occurred in at least one of the enrolled patients

From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

Event

All grade-no.(%)

Grade 3–4-no.(%)

Neutrophil count decreased

21(30)

5 (7)

Platelet count decreased

23 (33)

5 (7)

Anemia

12 (17)

2 (2)

Alopecia

2 (2)

/

Diarrhea

1 (1)

/

Nausea

8 (12)

2 (2)

Vomiting

5 (7)

2 (2)